poisar

Stocks · News reference

Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54

Benzinga Newsdesk

Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VCYT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

    Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

    CORGMEDVCYTWST
  2. Na

    TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

    Thermo Fisher Scientific unveiled the EMPAD G2 detector, enabling faster 4D STEM materials analysis at 10,000 frames per second with atomic-scale characterization. The detector integrates with Velox software for simplified analysis. The global 4D STEM market is projected to grow from $68 million in 2024 to $110 million by 2031 at a 6.6% CAGR, supporting TMO's growth prospects in analytical instruments.

    TMOGMEDVCYTILMN
  3. Na

    Neogen Surges 102.8% in a Year: What's Driving the Rally?

    Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.

    NEOGGMEDVCYTILMN
  4. Na

    Should You Add Illumina Stock to Your Portfolio Now?

    Illumina (ILMN) raised its 2026 revenue and EPS guidance following a 9.5% year-over-year revenue increase in Q2, driven by strong oncology clinical growth and expanded multiomics offerings. However, the company faces margin pressure from tariffs, freight costs, and memory inflation, with adjusted gross margin declining 120 basis points year-over-year despite manageable leverage and sufficient liquidity.

    ILMNGMEDVCYTTFX